Astatine-211 phenylalanine - Telix Pharmaceuticals
Alternative Names: TLX-102; TLX102 (211At-APA)Latest Information Update: 09 Jan 2025
Price :
$50 *
At a glance
- Originator Telix Pharmaceuticals
- Class Antineoplastics; Radioisotopes; Radiopharmaceuticals; Small molecules
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Brain cancer
Most Recent Events
- 19 Nov 2024 Preclinical trials in Brain cancer in Australia (Parenteral) (Telix Pharmaceuticals pipeline, November 2024)
- 31 Aug 2020 Astatine-211 phenylalanine receives Orphan Drug status for Multiple myeloma in USA (Telix Pharmaceuticals website, November 2024)